About: AM-1220

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

AM-1220 is a drug that acts as a potent and moderately selective agonist for the cannabinoid receptor CB1, with around 19 times selectivity for CB1 over the related CB2 receptor. It was originally invented in the early 1990s by a team led by Thomas D'Ambra at Sterling Winthrop, but has subsequently been researched by many others, most notably the team led by Alexandros Makriyannis at the University of Connecticut. The (piperidin-2-yl)methyl side chain of AM-1220 contains a stereocenter, so there are two enantiomers with quite different potency, the (R)-enantiomer having a Ki of 0.27 nM at CB1 while the (S)-enantiomer has a much weaker Ki of 217 nM.

Property Value
dbo:abstract
  • AM-1220 is a drug that acts as a potent and moderately selective agonist for the cannabinoid receptor CB1, with around 19 times selectivity for CB1 over the related CB2 receptor. It was originally invented in the early 1990s by a team led by Thomas D'Ambra at Sterling Winthrop, but has subsequently been researched by many others, most notably the team led by Alexandros Makriyannis at the University of Connecticut. The (piperidin-2-yl)methyl side chain of AM-1220 contains a stereocenter, so there are two enantiomers with quite different potency, the (R)-enantiomer having a Ki of 0.27 nM at CB1 while the (S)-enantiomer has a much weaker Ki of 217 nM. (en)
dbo:casNumber
  • (racemic)
  • 134959-64-1 ((R)-enantiomer)
  • 137642-54-7
dbo:fdaUniiCode
  • 05850M72P2
  • 44NQ9RBE1B
dbo:pubchem
  • 9929889
dbo:thumbnail
dbo:wikiPageID
  • 32279166 (xsd:integer)
dbo:wikiPageLength
  • 6456 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1090390113 (xsd:integer)
dbo:wikiPageWikiLink
dbp:c
  • 26 (xsd:integer)
dbp:casNumber
  • 137642 (xsd:integer)
dbp:casSupplemental
  • 134959 (xsd:integer)
  • (en)
dbp:chemspiderid
  • 26231035 (xsd:integer)
dbp:h
  • 26 (xsd:integer)
dbp:index2Label
  • -enantiomer (en)
dbp:iupacName
  • -methanone (en)
dbp:legalAu
  • S9 (en)
dbp:legalCa
  • Schedule II (en)
dbp:legalDe
  • Anlage II (en)
dbp:legalNz
  • Temporary Class (en)
dbp:legalUk
  • Class B (en)
dbp:legalUs
  • Schedule I (en)
dbp:n
  • 2 (xsd:integer)
dbp:o
  • 1 (xsd:integer)
dbp:pubchem
  • 9929889 (xsd:integer)
dbp:smiles
  • O=CC3=CNC5=CC=CC=C53 (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • URKVBEKZCMUTQC-HXUWFJFHSA-N (en)
dbp:unii
  • 44 (xsd:integer)
  • 5850 (xsd:integer)
dbp:verifiedrevid
  • 454826769 (xsd:integer)
dbp:width
  • 200 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • AM-1220 is a drug that acts as a potent and moderately selective agonist for the cannabinoid receptor CB1, with around 19 times selectivity for CB1 over the related CB2 receptor. It was originally invented in the early 1990s by a team led by Thomas D'Ambra at Sterling Winthrop, but has subsequently been researched by many others, most notably the team led by Alexandros Makriyannis at the University of Connecticut. The (piperidin-2-yl)methyl side chain of AM-1220 contains a stereocenter, so there are two enantiomers with quite different potency, the (R)-enantiomer having a Ki of 0.27 nM at CB1 while the (S)-enantiomer has a much weaker Ki of 217 nM. (en)
rdfs:label
  • AM-1220 (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License